HER2 loss after neoadjuvant treatment: Is the adjuvant trastuzumab treatment feasible?

HER2 loss after neoadjuvant treatment: Is the adjuvant trastuzumab treatment feasible?

Furthermore, another study looked at the prevalence and prognostic impact of HER2 loss in breast cancer patients with HER2-positive disease treated with neoadjuvant weekly paclitaxel plus carboplatin with or without trastuzumab (PCH versus PC) [2]. 1 Z. Xian, A.K. Quinones, G. Tozbikian, D.L. Zynger...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human pathology 2017-07, Vol.65, p.247-247
1. Verfasser: Altundag, Kadri, MD
Format: Artikel
Sprache:eng
Schlagworte:
Biopsy
Breast cancer
Cancer therapies
Chemotherapy
Immunotherapy
Medical prognosis
Monoclonal antibodies
Pathology
Targeted cancer therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Furthermore, another study looked at the prevalence and prognostic impact of HER2 loss in breast cancer patients with HER2-positive disease treated with neoadjuvant weekly paclitaxel plus carboplatin with or without trastuzumab (PCH versus PC) [2]. 1 Z. Xian, A.K. Quinones, G. Tozbikian, D.L. Zynger, Hum Pathol, Vol. 62, 2017, 215-221 2 R.X. Wang, S. Chen, X. Jin, C.M. Chen, Z.M. Shao, Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis, Breast Cancer Res Treat, Vol. 161, 2017, 259-267 3 B. Hacioglu, S. Akin, A.R. Sever, K. Altundag, Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients, Future Oncol, Vol. 11, 2015, 2495-2497
ISSN:0046-8177
1532-8392
DOI:10.1016/j.humpath.2017.02.025